Symbol="TCRT"
AssetType="Common Stock"
Name="Alaunos Therapeutics Inc"
Description="Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas."
CIK="1107421"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="100269000"
EBITDA="-30559000"
PERatio="None"
PEGRatio="None"
BookValue="0.123"
DividendPerShare="0"
DividendYield="0"
EPS="-0.16"
RevenuePerShareTTM="0.013"
ProfitMargin="0"
OperatingMarginTTM="-11.4"
ReturnOnAssetsTTM="-0.312"
ReturnOnEquityTTM="-0.966"
RevenueTTM="2922000"
GrossProfitTTM="-19596000"
DilutedEPSTTM="-0.16"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="6.31"
AnalystTargetPrice="3.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="50.84"
PriceToBookRatio="5.02"
EVToRevenue="51.16"
EVToEBITDA="-4.306"
Beta="0.163"
num_52WeekHigh="4.01"
num_52WeekLow="0.41"
num_50DayMovingAverage="0.476"
num_200DayMovingAverage="0.646"
SharesOutstanding="240627000"
DividendDate="None"
ExDividendDate="None"
symbol="TCRT"
open="0.41"
high="0.43"
low="0.41"
price="0.41"
volume="563507.00"
latest_trading_day="2023-08-07"
previous_close="0.42"
change="-0.01"
change_percent="-1.9438%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="78"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="22"
Volume_recent_avg="541759"
Change_recent_avg="-0.01"
Delta_recent_avg="0.04"
Variance_recent_avg="0.02"
Change_ratio_recent_avg="-1.16"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="22"
Aroon_momentum_negative="78"
image_negative_thumbnail_id_1="172"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0004.jpeg"
image_negative_thumbnail_id_2="500"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0105.jpeg"
image_neutral_thumbnail_id_1="565"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0034.jpeg"
image_neutral_thumbnail_id_2="528"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0071.jpeg"
image_positive_thumbnail_id_1="638"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0070.jpeg"
image_positive_thumbnail_id_2="671"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0037.jpeg"
image_professor_thumbnail_id_1="1182"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
image_professor_thumbnail_id_2="1195"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
